The importance of CDKN2A/B chromosomal loss has since already been established as precision medicine target in other malignancies, such as melanomas, 10 non-small lung cancer, 38, 39 and urothelial carcinoma 41 by reconstituting the tumor suppressing effect of CDKN2A/B. Here, CDKN2A is linked to urothelial carcinoma.